Thornburg Investment Management Inc. Raises Stake in Stevanato Group S.p.A. (NYSE:STVN)

Thornburg Investment Management Inc. boosted its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 48.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,122,098 shares of the company’s stock after buying an additional 364,471 shares during the period. Thornburg Investment Management Inc.’s holdings in Stevanato Group were worth $24,451,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of STVN. Van Berkom & Associates Inc. acquired a new stake in shares of Stevanato Group in the fourth quarter worth $39,000. Johnson Financial Group Inc. acquired a new position in shares of Stevanato Group during the fourth quarter worth $41,000. Wells Fargo & Company MN grew its holdings in Stevanato Group by 680.3% during the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company’s stock valued at $71,000 after purchasing an additional 2,830 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after buying an additional 5,291 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Stevanato Group by 202.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company’s stock worth $162,000 after buying an additional 4,965 shares during the period.

Stevanato Group Stock Up 2.8%

Shares of Stevanato Group stock opened at €23.97 ($26.63) on Friday. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average price of €21.41 and a 200 day moving average price of €21.18. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.40) and a fifty-two week high of €24.96 ($27.73). The firm has a market cap of $7.26 billion, a P/E ratio of 51.00, a P/E/G ratio of 7.18 and a beta of 0.51.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. On average, sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be issued a dividend of $0.0613 per share. This represents a dividend yield of 0.3%. This is a boost from Stevanato Group’s previous annual dividend of $0.05. The ex-dividend date of this dividend is Thursday, June 5th. Stevanato Group’s dividend payout ratio is 11.76%.

Analysts Set New Price Targets

STVN has been the subject of several recent analyst reports. Stephens upgraded Stevanato Group to a “strong-buy” rating in a research note on Monday, April 21st. William Blair restated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Finally, UBS Group cut their target price on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of €25.70 ($28.56).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.